Illumina posts higher first-quarter profit and sales, raises guidance
Updated
Updated · MarketWatch · Apr 30
Illumina posts higher first-quarter profit and sales, raises guidance
10 articles · Updated · MarketWatch · Apr 30
The genomics company reported profit of $134 million, or 87 cents a share, on revenue of $1.09 billion, beating FactSet expectations; adjusted earnings were $1.15 a share.
Illumina said growing demand for its NovaSeq X sequencing system drove results as clinical customers expanded into new application areas, according to chief executive Jacob Thaysen.
It now expects 2026 revenue of $4.52 billion to $4.62 billion and adjusted earnings of $5.15 to $5.30 a share, both above its previous outlook.
With Illumina's NovaSeq X innovations and expanding clinical reach, how might rivals respond—and could any disrupt its market dominance?
As AI and genomics merge, what ethical or societal challenges could arise from the rapid adoption of whole genome sequencing in healthcare?